Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.31 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16698887 | 1.00 | POLRMT (0.58) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL16698886 | 1.00 | POLRMT (0.58) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL31228208 | 1.00 | POLRMT (0.58) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL16698885 | 1.00 | POLRMT (0.58) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL16708584 | 0.92 | POLRMT (0.47) | POLRMTCYP3A4CYP2C9BTN3A1 | |
| SCHEMBL26283386 | 0.88 | POLRMT (0.41) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL26286838 | 0.88 | POLRMT (0.41) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL20960078 | 0.88 | POLRMT (0.41) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL26283347 | 0.88 | POLRMT (0.41) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L | |
| SCHEMBL26283421 | 0.88 | POLRMT (0.41) | POLRMTCYP3A4CYP2C9BTN3A1DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3505173-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9388208-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | ROSEMOUNT INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | POLRMT 306/4885CYP3A4 1982/4885CYP2C9 3912/4885 |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | POLRMT 306/4885CYP3A4 1982/4885CYP2C9 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.